Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Qingshan Huang, Chenglong Chen, Jingbing Lou, Yi Huang, Tingting Ren & Wei Guo. (2021) Development of a Nomogram for Predicting the Efficacy of Preoperative Chemotherapy in Osteosarcoma. International Journal of General Medicine 14, pages 4819-4827.
Read now
Read now
Dexing Wang, Guowei Qian, Jin Wang, Tian Wang, Lian Zhang, Ping Yang & Feng Lin. (2019) Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1. Cancer Biology & Therapy 20:7, pages 999-1006.
Read now
Read now
Claudia Maria Hattinger, Maria Pia Patrizio, Federica Magagnoli, Silvia Luppi & Massimo Serra. (2019) An update on emerging drugs in osteosarcoma: towards tailored
therapies?. Expert Opinion on Emerging Drugs 24:3, pages 153-171.
Read now
Read now
Claudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, Federica Magagnoli, Piero Picci & Massimo Serra. (2019) Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. Expert Opinion on Drug Metabolism & Toxicology 15:4, pages 299-311.
Read now
Read now
Claudia Maria Hattinger, Maria Pia Patrizio, Elisa Tavanti, Silvia Luppi, Federica Magagnoli, Piero Picci & Massimo Serra. (2018) Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. Expert Review of Molecular Diagnostics 18:11, pages 947-961.
Read now
Read now
Claudia Maria Hattinger, Elisa Tavanti, Marilù Fanelli, Serena Vella, Piero Picci & Massimo Serra. (2017) Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 245-257.
Read now
Read now
Marie-Françoise Heymann, Hannah K. Brown & Dominique Heymann. (2016) Drugs in early clinical development for the treatment of osteosarcoma. Expert Opinion on Investigational Drugs 25:11, pages 1265-1280.
Read now
Read now
Zhiguo Chen, Shenghai Qiu & Xiaofei Lu. (2015) The expression and clinical significance of HDGF in osteosarcoma. OncoTargets and Therapy 8, pages 2509-2517.
Read now
Read now
Articles from other publishers (63)
Siyuan Huang, Dong Zhang, Xinzeyu Yi, Changjiang Liu, Chao Jian & Aixi Yu. (2023) 3-AP inhibits the growth of human osteosarcoma by decreasing the activity of the iron-dependent pathway. Medical Oncology 40:12.
Crossref
Crossref
Liu JunLi XuhongLiu Hui. (2023) Circ_SIPA1L1 Promotes Osteosarcoma Progression Via miR-379-5p/MAP3K9 Axis. Cancer Biotherapy and Radiopharmaceuticals 38:9, pages 604-618.
Crossref
Crossref
Bo Yang, Bowen Wang, Guoliang Wang, Wenliang Cao, Qian Wang, Hao Pu & Wei An. (2023) p-Coumaric Acid Inhibits Osteosarcoma Growth by Inhibiting PI3K/Akt Signaling
Pathway. Anti-Cancer Agents in Medicinal Chemistry 23:13, pages 1577-1586.
Crossref
Crossref
Lei Yan, Ruoqi Li, Dijun Li, Yuanyuan Zhu, Zhi Lv & Bin Wang. (2023) Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients. Clinical and Translational Oncology 25:12, pages 3501-3518.
Crossref
Crossref
Shengwen Cheng, Senrui Liu, Bowen Chen, Chengcheng Du, Pengcheng Xiao, Xuefeng Luo, Li Wei, Yiting Lei, Chen Zhao & Wei Huang. (2023) Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways. Chinese Medicine 18:1.
Crossref
Crossref
Lei Zhang, Ying-Xuan Liu, Ya-Ting Yao, Tian-Jiao Zhou, Hu-Lin Jiang & Cheng-jun Li. (2023) Injectable rhein-assisted crosslinked hydrogel for efficient local osteosarcoma chemotherapy. International Journal of Pharmaceutics 634, pages 122637.
Crossref
Crossref
Qiong Xi & Jinqi Ma. (2023) Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) as a Chemosensitivity-Related Biomarker for Osteosarcoma. Journal of Oncology 2023, pages 1-12.
Crossref
Crossref
Dan Fei, Hongping Yuan, Mingming Zhao & Dongxu Zhao. (2022) LncRNA FGD5‐AS1 potentiates autophagy‐associated doxorubicin resistance by regulating the miR‐154‐5p/WNT5A axis in osteosarcoma. Cell Biology International 46:11, pages 1937-1946.
Crossref
Crossref
Natalia Todosenko, Kristina Yurova, Olga Khaziakhmatova, Vladimir Malashchenko, Igor Khlusov & Larisa Litvinova. (2022) Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. Pharmaceutics 14:10, pages 2181.
Crossref
Crossref
Chunmei Yang, Lulu Zhang, Huakun Huang, Xiaohui Yuan, Ping Zhang, Caihong Ye, Mengqi Wei, Yanran Huang, Xiaoji Luo & Jinyong Luo. (2022) Alantolactone inhibits proliferation, metastasis and promotes apoptosis of human osteosarcoma cells by suppressing Wnt/β-catenin and MAPKs signaling pathways. Genes & Diseases 9:2, pages 466-478.
Crossref
Crossref
Wei-Nan Zeng, Qiu-Ping Yu, Duan Wang, Jun-Li Liu, Qing-Jun Yang, Zong-Ke Zhou & Yi-Ping Zeng. (2021) Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Hirokazu Ideta, Kazushige Yoshida, Masanori Okamoto, Jun Sasaki, Munehisa Kito, Kaoru Aoki, Yasuo Yoshimura, Shuichiro Suzuki, Atsushi Tanaka, Akira Takazawa, Hisao Haniu, Takeshi Uemura, Takashi Takizawa, Atsushi Sobajima, Takayuki Kamanaka, Jun Takahashi, Hiroyuki Kato & Naoto Saito. (2021) Antitumor Effect of Sclerostin against Osteosarcoma. Cancers 13:23, pages 6015.
Crossref
Crossref
A.G. Nerkar. (2021) Osteosarcoma: A review. Current Trends in Pharmacy and Pharmaceutical Chemistry 3:4, pages 35-37.
Crossref
Crossref
José Miguel P. Ferreira de Oliveira, Joana Filipa D. Almeida, Maria Martins, Carina Proença, Helena Oliveira, Eduarda Fernandes & Conceição Santos. (2021) 3′,4′-Dihydroxyflavonol Modulates the Cell Cycle in Cancer Cells: Implication as a Potential Combination Drug in Osteosarcoma. Pharmaceuticals 14:7, pages 640.
Crossref
Crossref
Ming Li & Wei Ma. (2021) miR-26a Reverses Multidrug Resistance in Osteosarcoma by Targeting MCL1. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Xunming Zhao, Weichun Guo, Lixue Zou & Biao Hu. (2020) FBXO2 modulates STAT3 signaling to regulate proliferation and tumorigenicity of osteosarcoma cells. Cancer Cell International 20:1.
Crossref
Crossref
Wei Wei, Liefeng Ji, Wanli Duan & Jiang Zhu. (2020) CircSAMD4A contributes to cell doxorubicin resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis. Open Life Sciences 15:1, pages 848-859.
Crossref
Crossref
Xiaoli Wang, Lili Zhang, Xingfeng Zhang, Cuihong Xing, Ruidong Liu & Fang Zhang. (2020) MiR-196a promoted cell migration, invasion and the epithelial-mesenchymal transition by targeting HOXA5 in osteosarcoma. Cancer Biomarkers 29:2, pages 291-298.
Crossref
Crossref
Xiaohan Mao, Yaqian Jin, Tianyu Feng, Hao Wang, Dan Liu, Zhangxu Zhou, Qi Yan, Huini Yang, Jieru Yang, Jing Yang, Yan Ye, Yuxi Su & Guowei Zuo. (2020)
Ginsenoside Rg3 Inhibits the Growth of Osteosarcoma and Attenuates Metastasis through the Wnt/
β
-Catenin and EMT Signaling Pathway
. Evidence-Based Complementary and Alternative Medicine 2020, pages 1-12.
Crossref
Crossref
Dimas Carolina Belisario, Muhlis Akman, Martina Godel, Virginia Campani, Maria Pia Patrizio, Lorena Scotti, Claudia Maria Hattinger, Giuseppe De Rosa, Massimo Donadelli, Massimo Serra, Joanna Kopecka & Chiara Riganti. (2020) ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. Cells 9:3, pages 647.
Crossref
Crossref
Qinwen Li, Jie Liang & Bo Chen. (2020) Identification of CDCA8, DSN1 and BIRC5 in Regulating Cell Cycle and Apoptosis in Osteosarcoma Using Bioinformatics and Cell Biology. Technology in Cancer Research & Treatment 19, pages 153303382096560.
Crossref
Crossref
Sai Batchu & Justin Lee Gold. (2020) Analysis of Transcriptomic Similarity between Osteosarcoma Cell Lines and Primary Tumors. Oncology 98:11, pages 814-816.
Crossref
Crossref
Massimo Serra & Claudia Maria Hattinger. 2020. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions
213
215
.
Zhiqiang Li, Renjie Xu, Xiangxin Zhang, Jun Shen, Guangxiang Chen, Tianming Zou & Xiao Yu. (2019) Interleukin‑22 modulates cisplatin sensitivity of osteosarcoma cells by regulating the STAT3 signaling pathway. Experimental and Therapeutic Medicine.
Crossref
Crossref
Patrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, Alberto Righi, Giordano Nicoletti, Camilla Cristalli, Michela Pasello, Alessandro Parra, Marianna Carrabotta, Manuela Ferracin, Arianna Palladini, Marianna L. Ianzano, Veronica Giusti, Francesca Ruzzi, Mauro Magnani, Davide Maria Donati, Piero Picci, Pier-Luigi Lollini & Katia Scotlandi. (2019) Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports 9:1.
Crossref
Crossref
Elena Gazzano, Ilaria Buondonno, Alessandro Marengo, Barbara Rolando, Konstantin Chegaev, Joanna Kopecka, Simona Saponara, Matteo Sorge, Claudia Maria Hattinger, Alberto Gasco, Roberta Fruttero, Mara Brancaccio, Massimo Serra, Barbara Stella, Elias Fattal, Silvia Arpicco & Chiara Riganti. (2019) Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Letters 456, pages 29-39.
Crossref
Crossref
Francesca Perut, Laura Roncuzzi, Nicoletta Zini, Annamaria Massa & Nicola Baldini. (2019) Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis. Cancers 11:6, pages 779.
Crossref
Crossref
Yichi Zhou, Qi Jin, Wei Xiao & Chengjun Sun. (2019) Tankyrase1 antisense oligodeoxynucleotides suppress the proliferation, migration and invasion through Hippo/YAP pathway in human osteosarcoma cells. Pathology - Research and Practice 215:6, pages 152381.
Crossref
Crossref
Xiuxin Han, Fengting Liu, Chao Zhang, Zhiwu Ren, Lili Li & Guowen Wang. (2019) SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells. Biological Chemistry 400:4, pages 545-553.
Crossref
Crossref
Maria Carolina Ruiz, Agustina Resasco, Ana Laura Di Virgilio, Miguel Ayala, Isabel Cavaco, Silvia Cabrera, Jose Aleman & Ignacio Esteban León. (2019) In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models. Cancer Chemotherapy and Pharmacology 83:4, pages 681-692.
Crossref
Crossref
Wenpei Fan, Wei Tang, Joseph Lau, Zheyu Shen, Jin Xie, Jianlin Shi & Xiaoyuan Chen. (2019) Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics. Advanced Materials 31:12.
Crossref
Crossref
Kjetil Berner, Tom Børge Johannesen, Kirsten Sundby Hall & Øyvind S. Bruland. (2019) Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas – A nationwide population-based study. Journal of Bone Oncology 14, pages 100207.
Crossref
Crossref
Ilaria Buondonno, Elena Gazzano, Elisa Tavanti, Konstantin Chegaev, Joanna Kopecka, Marilù Fanelli, Barbara Rolando, Roberta Fruttero, Alberto Gasco, Claudia Hattinger, Massimo Serra & Chiara Riganti. (2018) Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cellular and Molecular Life Sciences 76:3, pages 609-625.
Crossref
Crossref
Zhen Wang, Xiao Chen, Yongqiang Zhao, Yi Jin & Jia Zheng. (2018) G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail. Journal of Cancer Research and Clinical Oncology 145:1, pages 87-96.
Crossref
Crossref
Hadeel Obiedat, Nasr Alrabadi, Eyad Sultan, Marwa Al Shatti & Malek Zihlif. (2018) The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. BMC Medical Genetics 19:1.
Crossref
Crossref
Elisa Martella, Claudia Ferroni, Andrea Guerrini, Marco Ballestri, Marta Columbaro, Spartaco Santi, Giovanna Sotgiu, Massimo Serra, Davide Donati, Enrico Lucarelli, Greta Varchi & Serena Duchi. (2018) Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. International Journal of Molecular Sciences 19:11, pages 3670.
Crossref
Crossref
Hong Pei, Liang Chen, Quan‑Ming Liao, Ke‑Jun Wang, Shun‑Guang Chen, Zheng‑Jie Liu & Zhi‑Cai Zhang. (2018) SUMO‑specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation. Experimental and Therapeutic Medicine.
Crossref
Crossref
Giulia Bernardini, Michela Geminiani, Silvia Gambassi, Maurizio Orlandini, Elena Petricci, Barbara Marzocchi, Marcella Laschi, Maurizio Taddei, Fabrizio Manetti & Annalisa Santucci. (2018) Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. Journal of Cellular Physiology 233:6, pages 4961-4971.
Crossref
Crossref
Fan Yang, Xi Wen, Qin-Fei Ke, Xue-Tao Xie & Ya-Ping Guo. (2018) pH-responsive mesoporous ZSM-5 zeolites/chitosan core-shell nanodisks loaded with doxorubicin against osteosarcoma. Materials Science and Engineering: C 85, pages 142-153.
Crossref
Crossref
Yuchun Li & Yuxian Wu. (2018) MiR-200-3p inhibits tumor cell proliferation and induces apoptosis by upregulation of FOXO1 in osteosarcoma cells. Molecular & Cellular Toxicology 14:1, pages 73-78.
Crossref
Crossref
Lingyun Lu, Zhehao Dai, Qing Luo & Guohua Lv. (2017) The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma. Molecular Medicine Reports.
Crossref
Crossref
Guo Dai, Di Zheng, Qianliang Wang, Jian Yang, Gaiwei Liu, Qi Song, Xiangran Sun, Chunjie Tao, Qingzhu Hu, Tian Gao, Ling Yu & Weichun Guo. (2017) Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway. Oncotarget 8:49, pages 86098-86116.
Crossref
Crossref
Zhu Kun-Peng, Ma Xiao-Long & Zhang Chun-Lin. (2017) LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. Oncotarget 8:42, pages 71881-71893.
Crossref
Crossref
Xi Xie, Yu-Sheng Li, Wen-Feng Xiao, Zhen-Han Deng, Hong-Bo He, Qing Liu & Wei Luo. (2017) MicroRNA-379 inhibits the proliferation, migration and invasion of human osteosarcoma cells by targetting EIF4G2. Bioscience Reports 37:3.
Crossref
Crossref
Zhengguang Wang, Zhendong Liu & Song Wu. (2017) Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget 8:19, pages 31465-31477.
Crossref
Crossref
Claudia M Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Chiara Riganti, Piero Picci & Massimo Serra. (2017) Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. Future Oncology 13:8, pages 673-677.
Crossref
Crossref
Zhenfeng Duan, Yan Gao, Jacson Shen, Edwin Choy, Gregory Cote, David Harmon, Karen Bernstein, Santiago Lozano-Calderon, Henry Mankin & Francis J. Hornicek. (2017)
miR-15b modulates multidrug resistance in human osteosarcoma
in vitro
and
in vivo
. Molecular Oncology 11:2, pages 151-166.
Crossref
Crossref
M Serra & C M Hattinger. (2016) The pharmacogenomics of osteosarcoma. The Pharmacogenomics Journal 17:1, pages 11-20.
Crossref
Crossref
Patrick F. Forde & Katie B. Ryan. 2017. Orthopedic Biomaterials. Orthopedic Biomaterials
569
604
.
Stefano Ferrari. 2017. Tumors of the Sacrum. Tumors of the Sacrum
373
382
.
Martin Sramek, Jakub Neradil, Jaroslav Sterba & Renata Veselska. (2016) Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation. Cancer Cell International 16:1.
Crossref
Crossref
Ryan A. Durfee, Maryam Mohammed & Hue H. Luu. (2016) Review of Osteosarcoma and Current Management. Rheumatology and Therapy 3:2, pages 221-243.
Crossref
Crossref
Serena Vella, Elisa Tavanti, Claudia Maria Hattinger, Marilù Fanelli, Rogier Versteeg, Jan Koster, Piero Picci & Massimo Serra. (2016) Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLOS ONE 11:11, pages e0166233.
Crossref
Crossref
Ran-Xi Zhang, Yang Li, Dong-Dong Tian, Yang Liu, Wu Nian, Xiang Zou, Qian-Zhao Chen, Lin-Yun Zhou, Zhong-Liang Deng & Bai-Cheng He. (2016) Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/β-catenin signaling in human osteosarcoma cells. International Journal of Oncology 49:5, pages 1973-1982.
Crossref
Crossref
Ilaria Buondonno, Elena Gazzano, Sae Rin Jean, Valentina Audrito, Joanna Kopecka, Marilù Fanelli, Iris C. Salaroglio, Costanzo Costamagna, Ilaria Roato, Eleonora Mungo, Claudia M. Hattinger, Silvia Deaglio, Shana O. Kelley, Massimo Serra & Chiara Riganti. (2016) Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Molecular Cancer Therapeutics 15:11, pages 2640-2652.
Crossref
Crossref
Hanneke I. Vos, Marieke J.H. Coenen, Henk-Jan Guchelaar & Dunja Maroeska W.M. te Loo. (2016) The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discovery Today 21:11, pages 1775-1786.
Crossref
Crossref
S. Scheil-Bertram & V. Krenn. (2016) Sitzungsbericht der AG Knochen-, Gelenk- und WeichgewebspathologieMinutes of the AG Knochen-, Gelenk- und Weichgewebspathologie. Der Pathologe 37:S2, pages 242-246.
Crossref
Crossref
Sara Westrøm, Tina B. Bønsdorff, Nasir Abbas, Øyvind S. Bruland, Thora J. Jonasdottir, Gunhild M. Mælandsmo & Roy H. Larsen. (2016) Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. PLOS ONE 11:10, pages e0165382.
Crossref
Crossref
Claudia M. Hattinger, Paola Biason, Erika Iacoboni, Sara Gagno, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Andrea Roli, Rossana Roncato, Luciana Giodini, Katia Scotlandi, Piero Picci, Giuseppe Toffoli & Massimo Serra. (2016) Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget 7:38, pages 61970-61987.
Crossref
Crossref
Konstantin Chegaev, Barbara Rolando, Daniela Cortese, Elena Gazzano, Ilaria Buondonno, Loretta Lazzarato, Marilù Fanelli, Claudia M. Hattinger, Massimo Serra, Chiara Riganti, Roberta Fruttero, Dario Ghigo & Alberto Gasco. (2016)
H
2
S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance
. Journal of Medicinal Chemistry 59:10, pages 4881-4889.
Crossref
Crossref
Rui Wang, Freddie H. Fu & Bing Wang. (2016) Precision medicine for diagnosis and treatment of osteosarcoma. Oncology and Translational Medicine 2:2, pages 49-54.
Crossref
Crossref
Ruyi Zhang, Shujuan Yan, Jing Wang, Fang Deng, Yangliu Guo, Ya Li, Mengtian Fan, Qilin Song, Hongxia Liu, Yaguang Weng & Qiong Shi. (2015) MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2. Tumor Biology 37:3, pages 3479-3488.
Crossref
Crossref
Ander Abarrategi, Juan Tornin, Lucia Martinez-Cruzado, Ashley Hamilton, Enrique Martinez-Campos, Juan P. Rodrigo, M. Victoria González, Nicola Baldini, Javier Garcia-Castro & Rene Rodriguez. (2016) Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells International 2016, pages 1-13.
Crossref
Crossref